Neal Augenstein
@nealaugenstein.bsky.social
Reporter, @WTOP. In 2010 was 1st radio reporter using iPhone as main field production device. naugenstein@wtop.com. Stage 4 #lungcancer survivor since 11/2022.
Not sure a loving parent would ever characterize that their child could turn into a POS.
October 30, 2025 at 10:34 AM
Not sure a loving parent would ever characterize that their child could turn into a POS.
Glad to speak with Lester Holt and NBC's Dateline: True Crime Weekly podcast about the case. podcasts.apple.com/us/podcast/f...
Former TV anchor allegedly targeted by ex. A professor's murder. Plus, Aileen Wuornos, in her own words.
Podcast Episode · Dateline: True Crime Weekly · 10/30/2025 · 27m
podcasts.apple.com
October 30, 2025 at 10:31 AM
Glad to speak with Lester Holt and NBC's Dateline: True Crime Weekly podcast about the case. podcasts.apple.com/us/podcast/f...
What would Mr. Beast do?
October 29, 2025 at 2:37 PM
What would Mr. Beast do?
The frames often have moldings that 'soften' the 'scrattchability'
October 23, 2025 at 4:24 AM
The frames often have moldings that 'soften' the 'scrattchability'
Have lots of 120-degree angles here. Often for short distances of walls, connecting to doors. Very unsatisfying backscratcher.
October 23, 2025 at 4:22 AM
Have lots of 120-degree angles here. Often for short distances of walls, connecting to doors. Very unsatisfying backscratcher.
the experts will say "the OS data isn't fully mature," which means they're still studying that part, which will be included in future #NorthStar findings. All in all, I'm glad my team is forward-looking and aggressive in my treatment, and I feel empowered by the research! 🫁🔬🥂#LCSM #esmo25 #oncsky
October 18, 2025 at 2:01 PM
the experts will say "the OS data isn't fully mature," which means they're still studying that part, which will be included in future #NorthStar findings. All in all, I'm glad my team is forward-looking and aggressive in my treatment, and I feel empowered by the research! 🫁🔬🥂#LCSM #esmo25 #oncsky
The study showed that certain patients benefit more than others, depending on their particular mutation, whether they had more than 3 metastases, and whether surgery or radiation 'got all' of the remaining tumors. And on the ?, 'Does having LCT help patients live longer...'
October 18, 2025 at 2:00 PM
The study showed that certain patients benefit more than others, depending on their particular mutation, whether they had more than 3 metastases, and whether surgery or radiation 'got all' of the remaining tumors. And on the ?, 'Does having LCT help patients live longer...'
The study showed for patients with my particular mutation, EGFR 19 Deletion, who've had surgery or radiation, there's a 42% lower risk of my cancer progressing than if I was just taking my one-pill-a-day targeted therapy. I like that number :)
October 18, 2025 at 1:59 PM
The study showed for patients with my particular mutation, EGFR 19 Deletion, who've had surgery or radiation, there's a 42% lower risk of my cancer progressing than if I was just taking my one-pill-a-day targeted therapy. I like that number :)
..it's studying whether adding LCT (local consolidative therapy, which is either surgery or radiation) to targeted therapy actually keeps cx from spreading, and for how long (that's called PFS, which stands for 'progression-free survival.') #NorthStar says the answer is yes :)
October 18, 2025 at 1:59 PM
..it's studying whether adding LCT (local consolidative therapy, which is either surgery or radiation) to targeted therapy actually keeps cx from spreading, and for how long (that's called PFS, which stands for 'progression-free survival.') #NorthStar says the answer is yes :)